PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC

Inclusion Criteria: 1. Age ≥18 years old and ≤75 years old; 2. Clinically diagnosed as hepatocellular carcinoma, stage B/C of BCLC; 3. No history of severe arrhythmia or heart failure; 4. No history of severe ventilation dysfunction or severe pulmonary infection; 5. No acute or chronic renal failure, the creatinine clearance rate was \>40 mL/min; 6. Liver function Child A; 7. Blood routine: absolute neutrophils count ≥1.5×10\^9/L, Hb≥8.5g/L, PLT≥75×10\^9/L; 8. Coagulation function: INR≤2.3; 9. ECOG score \<2; 10. No local or systemic treatment, such as TACE, RFA, targeted drugs, traditional Chinese medicine, etc., before enrollment; 11. Expected survival ≥12 weeks; 12. At least one lesion can be measured and evaluated by CT/MRI according to RECIST 1.1 criteria; 13. Understand and sign the informed consent. Exclusion Criteria: 1. Pregnant or lactating women; 2. Patients with other malignant tumors; 3. patients with complicated mental illness; 4. patients who have participated in other clinical trials in the last three months; 5. known or suspected allergy to any drug related to the study; 6. Patients with positive immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) 7. Patients treated with other targeted drugs, PD-L1 antibody and other immunotherapy or FOLFOX systemic chemotherapy after inclusion; 8. Patients with ≥1 + proteinuria indicated by urine routine will receive 24-hour urine protein detection, and patients with ≥1g 24-hour urine protein will not be included in the group. 9. Active autoimmune diseases that require systemic treatment (use of disease-alleviating agents, such as corticosteroids or immunosuppressants) 10. Patients with uncontrolled hepatitis B/C infection 11. Other conditions that the researcher considers not suitable for inclusion in this study